Literature DB >> 7041598

Increase in plasma aldosterone during prolonged captopril treatment.

P Lijnen, J Staessen, R Fagard, A Amery.   

Abstract

Plasma aldosterone concentration was measured in seven patients before and during long-term angiotensin II suppression with captopril. Plasma aldosterone decreased initially from 62 to 9 pg/ml (p less than 0.01) after 1 month of captopril administration. Thereafter, it began to increase and after 1 year reached a level of 163 pg/ml, which significantly (p less than 0.01) exceeded the pretreatment value. During long-term captopril therapy, plasma renin activity remained elevated and plasma angiotensin II concentration suppressed. The mechanism responsible for the late increase in plasma aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. Body weight decreased initially, parallel to plasma aldosterone increase, but after 6 months increased again to reach its pretreatment level after 1 year. Nevertheless a sizable and lasting hypotensive effect was observed in all patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041598     DOI: 10.1016/0002-9149(82)90390-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

1.  Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers.

Authors:  F De Ponti; C Marelli; L D'Angelo; M Caravaggi; L Bianco; S Lecchini; G M Frigo; A Crema
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Mineralocorticoid Antagonism and Diabetic Kidney Disease.

Authors:  Yuliya Lytvyn; Lucas C Godoy; Rosalie A Scholtes; Daniël H van Raalte; David Z Cherney
Journal:  Curr Diab Rep       Date:  2019-01-23       Impact factor: 4.810

Review 3.  Aldosterone in the pathogenesis of chronic kidney disease and proteinuria.

Authors:  Yee Lu; Elaine Ku; Vito M Campese
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

4.  Mineralocorticoid receptor antagonism prevents hedonic deficits induced by a chronic sodium appetite.

Authors:  Michael J Morris; Elisa S Na; Alan Kim Johnson
Journal:  Behav Neurosci       Date:  2010-04       Impact factor: 1.912

Review 5.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

6.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01

7.  Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.

Authors:  Jonathan P Mochel; Martin Fink; Mathieu Peyrou; Antoine Soubret; Jérôme M Giraudel; Meindert Danhof
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

8.  Intensified inhibition of renin-angiotensin system: a way to improve renal protection?

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

Review 9.  Intensified inhibition of renin-angiotensin system: a way to improve renal protection?

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 10.  Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.

Authors:  Elaine Ku; Vito M Campese
Journal:  Pediatr Nephrol       Date:  2009-04-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.